GlycoEra AG

GlycoEra AG is a biotechnology startup based in Switzerland, founded in 2020. The company's slogan, "Advancing Glycan Mediated Therapy," encapsulates its mission to advance glycan-mediated therapy as the leading precision protein degradation company. GlycoEra's proprietary technology revolves around the development of bifunctional biologics (G-LyTACs) that are designed to bind to disease-causing proteins and transport them to the lysosome using naturally occurring endocytic receptors. This unique approach allows for the degradation and removal of disease-causing proteins from the body. The company's technology differs from intracellular protein degraders, such as PROTACs and molecular glues, as it can access extracellular and membrane proteins, thus unlocking new therapeutic areas for intervention. In January 2024, GlycoEra secured a Series A investment from prominent investors including Sofinnova Partners, 5AM Ventures, Roche Venture Fund, and Bristol-Myers Squibb. This funding is expected to fuel the company's efforts in advancing its innovative biologics and expanding its presence in the biotechnology and healthcare sectors. GlycoEra's commitment to pioneering glycan-mediated therapy positions it as a compelling prospect for venture capital investment and holds significant promise for disrupting therapeutic intervention in the biotechnology landscape.